Liver concerns trigger FDA hold on Achillion sovaprevir study
This article was originally published in Scrip
Executive Summary
Shares of Achillion Pharmaceuticals plunged 24.6%, or $2.06, in after-hours trading on 1 July after the company disclosed the FDA placed a clinical hold on the firm's Phase I trial testing whether there were any drug-drug interactions (DDIs) with its experimental hepatitis C virus (HCV) medicine sovaprevir (ACH-1625) and Norvir (ritonavir)-boosted Reyataz (atazanavir) after unanticipated elevations in ALT liver enzymes in multiple healthy participants were detected.